SCHEMBL4265122

SCHEMBL4265122

N#Cc1ccc(C=Cc2ccc3c(c2)NC(=O)CO3)cc1

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NR3C2 P08235 6/20 0.58
MMP12 P39900 1/20 0.50
ALDH1A1 P00352 5/20 0.49
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
KMT2A Q03164 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
PARP1 P09874 2/20 0.47
BRD4 O60885 1/20 0.46
CREBBP Q92793 1/20 0.46
TRPV1 Q8NER1 1/20 0.45
MAPT P10636 4/20 0.44
PKM P14618 1/20 0.44
RAF1 P04049 1/20 0.42
BRAF P15056 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13932047 1.00 NR3C2 (0.58) NR3C2MMP12ALDH1A1LMNASMN1; SMN2
SCHEMBL705560 0.84 MMP12 (0.59) NR3C2MMP12ALDH1A1SMN1; SMN2KMT2A
SCHEMBL4264918 0.84 NR3C2 (0.55) NR3C2MMP12ALDH1A1LMNASMN1; SMN2
SCHEMBL13932098 0.84 NR3C2 (0.55) NR3C2MMP12ALDH1A1LMNASMN1; SMN2
SCHEMBL13932080 0.83 ALDH1A1 (0.67) NR3C2MMP12ALDH1A1LMNASMN1; SMN2
SCHEMBL4267374 0.83 ALDH1A1 (0.67) NR3C2MMP12ALDH1A1LMNASMN1; SMN2
SCHEMBL4258343 0.83 NR3C2 (0.53) NR3C2MMP12ALDH1A1LMNASMN1; SMN2
SCHEMBL13932051 0.83 NR3C2 (0.53) NR3C2MMP12ALDH1A1LMNASMN1; SMN2
SCHEMBL13932129 0.82 NR3C2 (0.62) NR3C2MMP12ALDH1A1LMNASMN1; SMN2
SCHEMBL4258190 0.82 NR3C2 (0.62) NR3C2MMP12ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
CN-101365696-A Compounds and compositions as modulators of steroid hormone nuclear receptors IRM LLC (BM) 2009-02-11 CN claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 NR3C2 7/4885MMP12 2999/4885ALDH1A1 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.